• Home
  • Browse
    • Current Issue
    • By Issue
    • By Author
    • By Subject
    • Author Index
    • Keyword Index
  • Journal Info
    • About Journal
    • Aims and Scope
    • Editorial Board
    • Publication Ethics
    • Indexing and Abstracting
    • Peer Review Process
  • Guide for Authors
  • Submit Manuscript
  • Contact Us
 
  • Login
  • Register
Home Articles List Article Information
  • Save Records
  • |
  • Printable Version
  • |
  • Recommend
  • |
  • How to cite Export to
    RIS EndNote BibTeX APA MLA Harvard Vancouver
  • |
  • Share Share
    CiteULike Mendeley Facebook Google LinkedIn Twitter
Afro-Egyptian Journal of Infectious and Endemic Diseases
arrow Articles in Press
arrow Current Issue
Journal Archive
Volume Volume 15 (2025)
Issue Issue 2
Issue Issue 1
Volume Volume 14 (2024)
Volume Volume 13 (2023)
Volume Volume 12 (2022)
Volume Volume 11 (2021)
Volume Volume 10 (2020)
Volume Volume 9 (2019)
Volume Volume 8 (2018)
Volume Volume 7 (2017)
Volume Volume 6 (2016)
Volume Volume 5 (2015)
Volume Volume 4 (2014)
Volume Volume 3 (2013)
Volume Volume 2 (2012)
Volume Volume 1 (2011)
Pumma, P., Tyagi, S., Wanswett, W., Loomba, P., Jain, M., Sharma, A. (2025). Unlocking Resistance: Evaluating Different Methods of Susceptibility Testing for Ceftazidime/Avibactam and Aztreonam Combination in MDR Gram-Negative Organisms. Afro-Egyptian Journal of Infectious and Endemic Diseases, 15(2), 179-183. doi: 10.21608/aeji.2025.337372.1431
Palak Pumma; Shivani Tyagi; Wanshisha Wanswett; Poonam Loomba; Manisha Jain; Abha Sharma. "Unlocking Resistance: Evaluating Different Methods of Susceptibility Testing for Ceftazidime/Avibactam and Aztreonam Combination in MDR Gram-Negative Organisms". Afro-Egyptian Journal of Infectious and Endemic Diseases, 15, 2, 2025, 179-183. doi: 10.21608/aeji.2025.337372.1431
Pumma, P., Tyagi, S., Wanswett, W., Loomba, P., Jain, M., Sharma, A. (2025). 'Unlocking Resistance: Evaluating Different Methods of Susceptibility Testing for Ceftazidime/Avibactam and Aztreonam Combination in MDR Gram-Negative Organisms', Afro-Egyptian Journal of Infectious and Endemic Diseases, 15(2), pp. 179-183. doi: 10.21608/aeji.2025.337372.1431
Pumma, P., Tyagi, S., Wanswett, W., Loomba, P., Jain, M., Sharma, A. Unlocking Resistance: Evaluating Different Methods of Susceptibility Testing for Ceftazidime/Avibactam and Aztreonam Combination in MDR Gram-Negative Organisms. Afro-Egyptian Journal of Infectious and Endemic Diseases, 2025; 15(2): 179-183. doi: 10.21608/aeji.2025.337372.1431

Unlocking Resistance: Evaluating Different Methods of Susceptibility Testing for Ceftazidime/Avibactam and Aztreonam Combination in MDR Gram-Negative Organisms

Article 8, Volume 15, Issue 2, June 2025, Page 179-183  XML PDF (540.19 K)
Document Type: Original Article
DOI: 10.21608/aeji.2025.337372.1431
View on SCiNiTO View on SCiNiTO
Authors
Palak Pummaorcid ; Shivani Tyagi email orcid ; Wanshisha Wanswettorcid ; Poonam Loombaorcid ; Manisha Jainorcid ; Abha Sharmaorcid
Department of Microbiology, Govind Ballabh Pant Institute of Postgraduate Medical Education and Research (GIPMER), New Delhi, India
Abstract
Background and study aim: Carbapenem-resistant bacterial strains are usually resistant to common treatment options, leading to significant morbidity and mortality. Beta-lactamase-mediated resistance is typically addressed by combining beta-lactam antibiotics with beta-lactamase inhibitors. However, when in case of resistance due to metallo-beta-lactamases, a third antibiotic is introduced to restore effectiveness. A recent combination, ceftazidime-avibactam (CAZ-AVI) and aztreonam (ATM) has shown promise. This study aimed to evaluate the in-vitro susceptibility of CAZ-AVI and ATM using three methods: MIC determination using E-test (with strip stacking and strip cross techniques) and disk elution, to identify a reliable and practical method for laboratory use.
Patients and Methods: In our study, 100 multidrug-resistant isolates were tested for susceptibility to CAZ-AVI and ATM, both individually and in combination, using the three testing methods.
Results: Of the 100 isolates resistant to both CAZ-AVI and ATM, 61% were sensitive to the CAZ-AVI/ATM combination by the E-strip method, and 64% were sensitive using the disk elution method. The results from all three methods were comparable, confirming their utility in testing this combination.
Conclusion: The current study highlighted the efficacy of the CAZ-AVI and ATM combination against multidrug-resistant organisms. The E-strip and disk elution methods were both effective for in-vitro testing. For isolates resistant to both CAZ-AVI and ATM individually, testing their combination is recommended to assess susceptibility.

Highlights
  • Ceftazidime/avibactam and aztreonam combination can be beneficial for patients infected with multidrug-resistant organisms.  
  • The E-strip and disk elution methods were both effective for in-vitro testing.
  • For isolates resistant to both CAZ-AVI and ATM individually, testing their combination is recommended to assess susceptibility.
Keywords
MDR gram negative organisms; ceftazidime-avibactam; aztreonam; treatment of multidrug-resistant organisms; susceptibility testing
Main Subjects
Infectious diseases
Full Text

INTRODUCTION

In the current period of rising resistance to antimicrobials, the issue of multi and pan-drug-resistant organisms is a major concern. Multi-drug-resistant gram-negative organisms are often treated with last-resort drugs like polymyxins, but the increasing use of these antibiotics has led to the development of resistance. Multi-drug resistant Enterobacterales and other gram-negative bacteria cause severe infections for which no defined treatment exists. These infections can be treated by a combination of aztreonam (ATM) with ceftazidime-avibactam (CZA), but no approved testing method is available for use in clinical laboratories to assess the activity of this combination [1,2]. 

However, different testing methods such as broth disk elution, disk stacking, gradient strip stacking, and strip crossing can be used for testing the susceptibility for this combination [3].

No established treatment regimen is available for multi and pan drug resistant organisms, especially those producing metallo beta lactamases (MBL). Although last-resort antibiotics such as polymyxins are used, however their effectiveness is constrained due to their therapeutic window being narrow, which can result in toxicity and the development of resistance during treatment [4].

While aztreonam is stable against MBL enzymes, its effectiveness as a stand-alone treatment is limited due to the frequent co-occurrence of extended-spectrum β-lactamases. However, combining it with the β-lactamase inhibitor avibactam may provide a clinically effective option. Nonetheless, there are only a few studies that have explored this combination.

Although aztreonam is approved for the treatment of MBL-producing organisms, there is currently no Clinical and Laboratory Standards Institute (CLSI) approved method for susceptibility testing of ceftazidime-avibactam and aztreonam combination [5]. Hence, in this study, we have tested this combination of ceftazidime-avibactam alongside aztreonam using three different methods: E-strips with strip stacking and strip cross methods, as well as the disk elution method. The objective is to identify a reliable and easy-to-perform method for use in laboratories [6].

MATERIALS AND METHODS

100 Multidrug-resistant bacterial strains were collected in the department of microbiology at a tertiary care super specialty hospital in New Delhi, over a period of one year. These strains were isolated from different samples received in the laboratory like body fluids, respiratory secretions, and blood. Then the susceptibility of the ceftazidime/avibactam and aztreonam combination was tested against these multidrug-resistant Gram-negative bacterial strains.

Testing methods

To assess the performance of these three different testing methods, MDR strains resistant to both ceftazidime avibactam and aztreonam were tested.

Susceptibility of ceftazidime/avibactam and aztreonam combination was tested by various methods like Gradient strip-based susceptibility testing (strip stacking method, Strip cross method) and Disk elution method and the results obtained by different methods were compared.

E-strips-based susceptibility testing: In the strip stacking method, an aztreonam gradient strip was placed on the surface of the Mueller Hinton agar plate inoculated with the lawn culture of the bacterial strain and allowed to diffuse for 10 minutes. After this, the aztreonam strip was removed, and a ceftazidime/avibactam strip was placed at the same place where the aztreonam strip was placed earlier. Finally, the aztreonam strip was placed on top of the ceftazidime/avibactam strip to determine the MIC values of aztreonam after incubation for 16–18 hours.

In the strip cross method, the aztreonam strip was initially placed on the agar surface, followed by the placement of the ceftazidime/avibactam strip perpendicularly at 8 mg/L for Enterobacterales and 16 mg/L for Pseudomonas aeruginosa isolates, which is the intermediate breakpoints of the respective organisms. After incubating at 37°C for 16–18 hours, the aztreonam MIC was read and interpreted according to CLSI criteria, with an aztreonam MIC value of ≤ 4 μg/ml considered susceptible.

Disk elution method: In tubes containing 2 mL of sterile Mueller-Hinton broth, aztreonam and ceftazidime/avibactam disks were added and allowed to elute for 30 minutes.12 μL of 0.5 McFarland bacterial suspension was added to the broth, resulting in a final bacterial count of approximately 105 CFU/ml. The absence of turbidity in the tube containing the disks was interpreted as susceptible.

STATISTICAL METHOD

All patient and laboratory data were entered in MS Excel spread sheet and analysis was done using SPSS software version 22.0, p-values of less than 0.05 was considered statistically significant. Data was analyzed for normality and descriptive statistics. Chi-square or Fisher's exact test was used for categorical variables.

RESULTS

A total of 100 different organisms like Klebsiella pneumoniae (43%), Acinetobacter baumannii (27%), Escherichia coli (18%), Pseudomonas aeruginosa (12%) were tested. Out of 100 isolates resistant to both ceftazidime-avibactam and aztreonam, 61 were found to be sensitive to the combination of CAZ-AVI and ATM using the E-strip susceptibility testing method, while 64 were sensitive according to the disk elution method.

Klebsiella pneumoniae and Escherichia coli exhibited the highest number of sensitive strains to the combination.

This emphasizes on the in vitro efficacy of a unique combination of CAZ-AVI and ATM in multidrug resistant isolates. The kappa agreement between the strip stacking and strip cross method was excellent (value 1.000) as compared between strip methods and disk elution method (value 0.794). The results demonstrated that findings from all three methods were comparable and could be utilized for in vitro testing of the ceftazidime/avibactam and aztreonam combination.

DISCUSSION

This study assesses three different methods for determining the in vitro efficacy of the ceftazidime-avibactam and aztreonam combination. Previous researchers have tested this combination using different approaches. For instance, an Indian study by Sahu et al. also observed synergy between the disk and E-strip methods [7]. In our study, three different methods i.e., the strip stacking method, the strip cross method, and the disk elution method for ceftazidime-avibactam and aztreonam combination were compared. While the results from all three methods were comparable, the kappa agreement between the strip stacking and strip cross methods was excellent (value 1.000), in contrast to the agreement between the strip methods and disk elution method (value 0.794).

This discrepancy may be attributed to the use of similar E-strips in both the strip stacking and strip cross methods, which share a comparable methodology. In contrast, the disk elution method employed ceftazidime/avibactam and aztreonam disks instead of E-strips, which could lead to differences in efficacy or erroneous results in one of the methods. A study by Khan et al. found complete agreement between the strip stacking and strip cross methods, aligning with our findings [2]. Similarly, another Indian study recommended implementing both strip-based and disk elution methods in clinical laboratories [5].

In terms of susceptibility, higher susceptibility was observed in Klebsiella pneumoniae and Escherichia coli strains, while the highest resistance was noted in Pseudomonas aeruginosa isolates. This may be due to non-carbapenemase resistance mechanisms, such as mutations in porins or efflux pumps, which align with findings from other studies. In an international study by Avery et al., gradient strip methods were recommended in the absence of molecular tests [8].

The need for such combinations is critical for treating patients with multidrug-resistant infections. In well-established laboratories, E-strip-based methods can be easily used, although they require proper training and expertise. On the other hand, in low-resource settings, the disk elution method is more practical, as it is cost-effective, does not require specialized training, and follows a simpler methodology. The interpretation of results in the disk elution method is straightforward, based on turbidity indicating resistance, whereas the E-strip method requires the interpretation of the MIC. However, the E-strip method provides the advantage of directly offering the MIC value, with growth observable on the plates. In contrast, turbidity in the disk elution method could result from contamination, which might not be detected visually.

Thus, both methods have their respective advantages and disadvantages, and the choice of method should depend on the laboratory setting and available resources.

CONCLUSION

Ceftazidime/avibactam and aztreonam combination can be beneficial for patients infected with multidrug-resistant organisms. While there is currently no standard testing method of testing available for this combination, both E-strip and disk elution methods are viable options for in vitro antibiotic susceptibility testing.

Ethical considerations:

Approval was taken from Institutional Ethics Committee before the start of the study. (IEC/68/EX/2023) No additional invasive specimens or intervention were taken for study purpose.

Author contribution: We declare that all listed authors have made substantial contributions to all of the following three parts of the manuscript:

- research design, or acquisition, analysis, or interpretation of data;

- drafting the paper or revising it critically;

- approving the submitted version.

We also declare that no one who qualifies for authorship has been excluded from the list of authors.

Funding: This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

Conflict of interest: The authors declare no potential conflict of interest

References
  1. Marshall S, Hujer AM, Rojas LJ, Papp-Wallace KM, Humphries RM, Spellberg B, et al. Can ceftazidime-avibactam and aztreonam overcome β-lactam resistance conferred by metallo-β-lactamases in Enterobacteriaceae?Antimicrob Agents Chemother. 2017;61(4):10-128.
  2. Khan A, Erickson SG, Pettaway C, Arias CA, Miller WR, Bhatti MM. Evaluation of susceptibility testing methods for aztreonam and ceftazidime-avibactam combination therapy on extensively drug-resistant gram-negative organisms. Antimicrob Agents Chemother. 2021;65(11):10-128.
  3. Biagi M, Wu T, Lee M, Patel S, Butler D, Wenzler E. Searching for the Optimal Treatment for Metallo-and Serine-β-Lactamase Producing Enterobacteriaceae: Aztreonam in Combination with Ceftazidime-avibactam or Meropenem-vaborbactam. Antimicrob Agents Chemother. 2019;63(12):e01426-19.
  4. Tsuji BT, Pogue JM, Zavascki AP, Paul M, Daikos GL, Forrest A, et al.International consensus guidelines for the optimal use of polymyxins: endorsed by the American College of Clinical Pharmacy (ACCP), European Society of Clinical Microbiology and Infectious Diseases (ESCMID), Infectious Diseases Society of America (IDSA), International Society for anti‐infective Pharmacology (ISAP), society of critical care medicine (SCCM), and society of infectious diseases pharmacists (SIDP). Pharmacother J Hum Pharmacol Drug Ther. 2019;39(1):10-39.
  5. Bakthavatchalam YD, Walia K, Veeraraghavan B. Susceptibility testing for aztreonam plus ceftazidime/avibactam combination: A general guidance for clinical microbiology laboratories in India.Indian J Med Microbiol. 2022;40(1):3-6.
  6. Sreenivasan P, Sharma B, Kaur S, Rana S, Biswal M, Ray P, et al. In-vitro susceptibility testing methods for the combination of ceftazidime-avibactam with aztreonam in metallocene-lactamase producing organisms: Role of combination drugs in antibiotic resistance era. J Antibiot (Tokyo). 2022;75(8):454-462.
  7. Sahu C, Pal S, Patel SS, Singh S, Gurjar M, Ghoshal U. Phenotypic synergy testing of ceftazidime–avibactam with aztreonam in a university hospital having a high number of metallobetalactamase producing bacteria. Infectious Diseases. 2020 Nov 1;52(11):801-7.
  8. Avery, Lindsay M., and David P. Nicolau. "Assessing the in vitro activity of ceftazidime/avibactam and aztreonam among carbapenemase-producing Enterobacteriaceae: defining the zone of hope." International journal of antimicrobial agents 52.5 (2018): 688-691.
Statistics
Article View: 200
PDF Download: 110
Home | Glossary | News | Aims and Scope | Sitemap
Top Top

Journal Management System. Designed by NotionWave.